Whalesbook
Analyst Deven Choksey has downgraded Supriya Lifescience to 'ACCUMULATE' from 'BUY', setting a target price of INR 850. The company reported a significant recovery in consolidated revenue, growing 37.7% Quarter-on-Quarter and 20.3% Year-on-Year to INR 1,998 million. This growth was driven by the resolution of operational bottlenecks, ramp-up of the Module E facility, and strong export performance contributing 81% of revenues.